



Article

Role of Educational Level in Kidney Transplant Outcomes

Francesco Leonforte ¹, Pierfrancesco Veroux ², Antonio Mistretta ², Alessia Giaquinta ³, Martina Maria Giambra ³, Domenico Zerbo ³, Giuseppe Roscitano ³, Concetta De Pasquale ³, Maria Luisa Pistorio ³, Antonio D'Anna ¹, Carmelo Cusmano ¹, Roberta Granata ⁴, Giordana Riccioli ⁴, Marianna Scribano ⁴ and Massimiliano Veroux ^{3,4},*

- Public Health Physician, University Hospital Polyclinic "G. Rodolico San Marco",95124 Catania, Italy; leonfortefrancesco1@gmail.com (F.L.); antoniodanna5@gmail.com (A.D.); cusmanocarmelo@gmail.com (C.C.)
- Department of Medical and Surgical Sciences and Advanced Technologies, University of Catania, 95124 Catania, Italy; pveroux@unict.it (P.V.); anmist@unict.it (A.M.)
- Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, 95121 Catania, Italy; alessiagiaquinta@gmail.com (A.G.); giambramartina@gmail.com (M.M.G.); domenicozerbo@libero.it (D.Z.); giuseppe.roscitano@virgilio.it (G.R.); depasqua@unict.it (C.D.P.); m.luisapistorio@unict.it (M.L.P.)
- General Surgery Unit, Azienda Policlinico San Marco, University of Catania, 95124 Catania, Italy; robertagranata@live.it (R.G.); giordanariccioli@me.com (G.R.); scribanomarianna@gmail.com (M.S.)
- * Correspondence: veroux@unict.it

Abstract: Background: Kidney transplantation outcomes are correlated to many factors, including the socioeconomics conditions and the educational level. Methods: We evaluated the role of educational level on patient and graft survival in a population of 456 kidney transplant recipients. Patients were divided into two groups on the basis of their pre-transplant educational status: patients with primary education (elementary or middle school, as low education) were compared with patients with a secondary school education (high school or a university degree, as high education). Results: Among the 456 patients considered for this analysis, 161 patients had a low educational status, and 295 had a high educational status. Patients with a low educational status were more rarely employed (66.1% vs. 32.5%, p < 0.001), with a high rate of retired patients compared to high-educational status patients (35.6% vs. 10.6%, p < 0.001). Although the educational status did not influence the graft function, the 1-year (88.1% vs. 96.2%, p = 0.0008), 5-year (77.6% vs. 88.8%, p = 0.001), and 10-year (62.1% vs. 75%, p = 0.003) graft survival rates were significantly lower in patients with low educational status compared with high-educational status patients, respectively. Patient survival at 1-year (94.4% vs. 97.6%, p = 0.073), 5-year (85% vs. 92.5%, p = 0.011), and 10-year (75.7% vs. 83.4%, p = 0.042) follow-up was significantly lower in patients with low educational status. Conclusions: Low socioeconomic conditions and educational level had a negative impact on kidney transplant outcomes. Improving access to education and providing targeted educational support and health literacy could enhance treatment adherence and reduce disparities in transplant outcomes.

Keywords: kidney transplantation; living donor; deceased donor; graft survival; patient survival; employment; work; socioeconomic conditions; educational status; income; quality of life



Academic Editors: Susana Coimbra and Alice Santos-Silva

Received: 13 March 2025 Revised: 29 March 2025 Accepted: 6 April 2025 Published: 9 April 2025

Citation: Leonforte, F.; Veroux, P.; Mistretta, A.; Giaquinta, A.; Giambra, M.M.; Zerbo, D.; Roscitano, G.; De Pasquale, C.; Pistorio, M.L.; D'Anna, A.; et al. Role of Educational Level in Kidney Transplant Outcomes. *Biomedicines* 2025, 13, 916. https://doi.org/10.3390/biomedicines13040916

Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

Kidney transplantation (KT) is the best available treatment for patients with endstage renal disease (ESRD); however, despite generally low long-term mortality risk after transplantation, recipients often face the challenge of allograft failure [1].

Health literacy, defined as the ability to acquire and comprehend health information to make suitable decisions, plays a significant role in healthcare utilization and patient Biomedicines **2025**, 13, 916

outcomes. Poor health literacy is linked to worse blood pressure control, higher hospital admissions, lower rates of preventive screenings like mammography and flu vaccination, and increased healthcare costs [2,3]. However, there is limited research on health literacy in the ESRD population scheduled for KT. Transplant candidates constitute a heterogeneous group, including patients with a long-term dialysis treatment together with patients undergoing a preemptive transplantation. Limited health literacy is likely common among KT candidates, potentially affecting their success in becoming listed and surviving on the KT waiting list: up to 12.9% of KT candidates with less than a college education and 4.8% of those with a college education experience limited health literacy [4].

This limited health literacy was independently associated with reduced chances of listing for transplantation and increased mortality once listed. The highest rates of limited health literacy are found among those who are frail, cognitively impaired, or have less than a college education. Screening for health literacy during KT evaluations could be crucial in addressing disparities in transplant access and waitlist outcomes [4–6]. Primary care physicians, nephrologists, and dialysis providers might help by providing adequate guidance, coordinating medical clearance steps for KT, and offering additional support through transplant patient navigators, as well as increasing awareness of waitlist status [7–9]. Although improving health literacy is challenging among KT candidates, tailored pre- and post-KT programs may be helpful to increase the outcomes of those with limited health literacy [4].

The quality of life in ESRD patients could be significantly impaired by the dialytic treatment and dietary restrictions, particularly for those with inadequate health literacy [10]. Limited health literacy may affect up to 25% of ESRD patients and is variably linked to negative clinical outcomes and to a limited access to transplantation [10–12]. In contrast, only 14% of transplant recipients experience limited literacy, suggesting a selection process favoring those with higher literacy [9,11,12]. Interestingly, among transplant recipients, young women are at a higher risk of graft failure than young men, while older women face similar or lower risks compared to older men [13]. This could be due to earlier cognitive development in females, enhancing their capacity for self-care, or a stronger social desirability tendency that affects adherence [14,15].

Patients with low health literacy often have low socioeconomic status (SES), which correlates with poorer ESRD comprehension and health outcomes [12].

SES and its factors, such as education level, income, and insurance coverage, significantly impact patient prognosis. Higher SES is linked to better graft and patient survival, as well as improved access to healthcare resources, and many studies showed that higher education levels correlate with better health literacy and medication adherence, improving transplant outcomes [16–19]. For instance, lower education is associated with increased graft failure risk in Black patients, whereas White patients with lower education face a lower mortality risk [20]. Ghods et al. [21] suggest that lower education may lead to poor transplant outcomes through reduced adherence to immunosuppressive regimens, whereas higher education levels are associated with better healthcare access and sustained use of immunosuppressants. Furthermore, recipients with higher education typically receive more social support, which positively affects transplant success. Consistent findings show better transplant outcomes in recipients with higher education, reinforcing the link between education level and successful transplant outcomes [22–24].

Overall, these studies underscore the importance of educational attainment as a determinant of health outcomes and quality of life in kidney transplant recipients. Understanding these relationships can inform strategies to optimize patient care and outcomes in the field of renal transplantation. In this study, we investigated the impact of educational level on post-transplant outcomes, with a special focus on graft and patient survival.

Biomedicines **2025**, 13, 916

2. Materials and Methods

In this study, we retrospectively evaluated the post-transplant outcomes of a cohort of kidney transplant recipients on the basis of their pre-transplant educational status: patients with primary education (elementary or middle school, as low education) were compared with patients with a secondary school education (high school or a university degree, as high education). Donor selection, kidney transplant procedures, and immunosuppressive therapy have been previously described in detail [25,26]. Delayed graft function was defined as the need for at least one dialysis session within one week after transplantation [26]. Primary kidney nonfunction was defined as the complete lack of functionality, so that the recipient never discontinued dialysis sessions after transplantation.

This study was approved by the Local Ethics Committee of the Azienda Policlinico San Marco of the University of Catania, and the patients provided written informed consent to undergo renal transplantation. A total of 456 consecutive patients who underwent a kidney transplantation from a deceased donor between January 2000 and December 2012 met the inclusion criteria and were included in this study.

Statistical Analysis

This study included all recipients of deceased donor kidneys recruited over a 12-year period. Data were retrieved from a password-protected institutional database, where patients were de-identified. The aim of this study was to evaluate the impact of education level on both post-transplant survival and graft survival. The variable "education level" was dichotomized to increase statistical power by dividing the transplanted patients into two categories (0: elementary or middle school; 1: high school or university degree). Characteristics at the time of transplant of patients with low educational levels were compared with patients with high educational levels with the use of Fisher's exact test, chi-square test, and Student's t-test. Predictive factors of worse graft and patient survival with a p-value < 0.5 in univariate analysis were considered for the multivariate model using a downward stepwise binary logistic regression analysis. Data are expressed as mean \pm standard deviation (SD). To compare parametric variables, either Pearson chi-square test or Fisher's exact test was used. To compare nonparametric variables, either Student's t-test or Mann–Whitney U test was used. The difference between the two means was calculated using the Wilson test. Odds ratios (ORs) were reported with a 95% confidence interval (95% CI) and p-values. The level of statistical significance was determined at p < 0.05. The primary analysis was a comparison of graft and patient survival rates with the Kaplan-Meier method. Since these were transplant patients, we assumed that the risks of graft loss and patient death would have decreased as time passed. We checked the fit of the Weibull model, assuming that the graph for the Weibull model with $\log(-\log(S-\text{estimate}))$ vs. $\log(\underline{t})$ should resemble a straight line. Since the graph according to the Weibull model did not deviate much from a straight line, we performed the regression using the Weibull model. The statistical analyses were performed with Stata 18.

3. Results

A total of 456 kidney transplant recipients were collected in the study period.

The mean age was 47.4 ± 16.4 years, with a prevalence of male recipients (286 patients, 62.7%) and a mean BMI of 26.6 ± 9.4 kg/m². The most frequent cause of end-stage renal disease was autosomal dominant polycystic kidney disease (91 patients, 19.9%), followed by glomerulonephritis (46 patients, 10.6%) and diabetes (22 patients, 4.8%), while the cause of ESRD was unknown in 162 (35.5%) of patients. Most patients (433 patients, 94.9%) were on hemodialysis at the time of transplantation, while seven patients (1.5%) received a pre-emptive kidney transplantation. Mean time on dialysis was 48 ± 23.2 months, while

Biomedicines **2025**, 13, 916 4 of 10

mean time on the waiting list was 19.2 ± 11.9 months. In the entire cohort, mean donor age was 51.4 ± 19.3 years, and a total of 23 donors (5.0%) had diabetes and 141 (30.9%) were hypertensive. A total of 161 patients had a low educational status, and 295 had a high educational status (Table 1).

Table 1. Clinical characteristics and comparison between the recipients with low educational status (n = 161) and those with high educational status (n = 295).

Done	Groups and their Characteristics	Low Educational Status (n = 161)	High Educational Status (n = 295)	<i>p</i> -Value
Mole sex (%) 78 (48.7) 108 (36.4) 0.013 Terminal serum creatinine (mg/dL) 1.06 ± 0.3 1.20 ± 0.7 0.061 Use of vasoactive amines (%) 155 (96.8) 275 (92.9) 0.832 Diabetes (%) 1.65 (96.8) 1.5 (27.9) 0.832 Cold is chemia time (h) 1.66 ± 1.2 1.5 (2.15) 0.003 Other causes of brain death 1.6 (2.2) 1.6 (3.2) 0.003 Other causes of brain death 5 (3.6) 1.9 (6.4) 0.017 Say in the ECT 5 (2.2) 0.001 Male sex (%) 94 (88.3) 1.94 (68.7) 0.138 Pre-transplant panel reactive antibody (%) 2.2 (8.1 + 1.9) 4.6 (8.1 + 1.2) 4.000 Male sex (%) 94 (88.3) 1.94 (68.7) 1.038 Pre-transplant panel reactive antibody (%) 2.2 (8.1 + 1.9) 4.5 (2.2 0.645 Time on dialysis (mo) 6.1 + 1.0 1.2 (1.9) 4.1 (1.9) 4.2 (1.9) 0.001 Time on dialysis (mo) 2.0 + 2.2 1.8 (2.2) 0.052 1.2 (2.2) 0.052 1.2 (2.2)				
Terminal serum creatinine (mg/dL)	Age (year)			
Use of vasoactive amines (%)				
Diabetes (%) 8 (5) 15 (5) 0.343 Cold is chemia time (h) 166 ± 5.1 15.2 ± 5.8 0.017 Cerebral hemorrhage/schemia brain death (%) 122 (76.2) 185 (62.5) 0.006 Traumatic brain death (%) 31 (19.3) 95 (62.0) 0.003 Other causes of brain death 8 (8) 19 (64.4) 0.017 Stay in the ICU 5 ± 5.4 1.9 (64.4) 0.001 Male sex (%) 94 (85.3) 194 (65.7) 0.18 Male sex (%) 94 (85.3) 194 (65.7) 0.74 Male sex (%) 94 (85.3) 194 (65.7) 0.74 Male sex (%) 14 (9.4) 94 (10.5) 0.74 Male sex (%) 24 (9.3) 194 (65.7) 0.74 Male sex (%) 24 (9.3) 194 (65.7) 0.74 Male sex (%) 46 (6.1) 41.3 ± 41 0.00 Male sex (%) 12 (19.4) 0.83 1.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 <td>Use of vasoactive amines (%)</td> <td></td> <td></td> <td></td>	Use of vasoactive amines (%)			
Cerebral hemorrhage/ischemia brain death (%) 1122 (76.2) 185 (82.5) 0.006 Traumatic brain death (%) 31 (19.3) 95 (32.0) 0.03 Other causes of brain death (%) 8 (5) 19 (6.4) 0.617 Say in the ICU 5.1 ± 3.9 0.824 Recipient Sc.08 ± 10.9 46.6 ± 12.4 <0.001 Male sex (%) 94 (58.3) 194 (65.7) 0.138 Pre-transplant panel reactive antibody (%) 24 ± 8.9 19 ± 85.7 0.74 BMI (mean, kg/m²) 27.4 26.2 0.65 Time on dialysis (mo) 61.9 ± 60 18.9 ± 25 0.50 Time on waiting list (mo) 159 (98.7) 27.9 (45.5) 0.885 Pertoneal dialysis (%) 159 (98.7) 27.9 (45.5) 0.885 Pertoneal dialysis (mo) 159 (89.7) 27.9 (45.5) 0.885 Pertoneal dialysis (mo) 159 (89.7) 27.9 (45.5) 0.885 Pertoneal dialysis (mo) 159 (87.7) 0.001 10.3 (3.3) 0.433 1.43 0.01 1.23 0.01 1.23 0.01			15 (5)	
Transport (γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ				
Other causes of brain death Stay in the CU 8 (9) 19 (6.4) 0.617 Recipient Secure 1 Color 1 Apple (9car) \$5.08 ± 10.9 46.6 ± 12.4 <0.001 Male sex (%) 94 (58.3) 194 (65.7) 0.138 Pre-transplant panel reactive antibody (%) 24 ± 8.9 19 ± 8.5 0.774 BMI (mean, kg/m²) 27.4 26.2 0.645 Time on dialysis (mo) 61.9 ± 0 41.3 ± 41 <0.001 Time on waiting list (mo) 20.6 ± 28 18.9 ± 25 0.502 Hemodialysis (%) 159 (98.7) 279 (94.5) 0.885 Pertoneal dialysis (fw) 10 (10) 10 (3.3) 0.433 Pertoneal dialysis (fw) 11 (1.3) 7 (2.3) 0.132 Pertoneal dialysis (fw) 8 (5.1) 6 (5.5) 0.023 Pertoneal dialysis (fw) 8 (5.1) 6 (5.5) 0.023 Pertoneal dialysis (fw) 8 (5.1) 6 (5.5) 0.013 Dual transplant (%) 8 (5.1) 6 (5.5) 0.733 Acute (fw) 2.1 0.1				
Resipient Recipient Age (year) \$2.08 ± 10.9 46.6 ± 12.4 <0.001			19 (6.4)	
Age (year) 52.08 ± 10.9 46.6 ± 12.4 <0.001 Male sex (%) 94 (58.3) 194 (65.7) 0.138 Pre-transplant panel reactive antibody (%) 24 ± 8.9 19 ± 8.5 0.774 BMI (mean, kg/m²) 27.4 26.2 0.645 Time on dialysis (mo) 61.9 ± 60 41.3 ± 41 <0.001 Time on waiting list (mo) 20.6 ± 28 18.9 ± 25 0.502 Hemodialysis (%) 0 (0) 10 (3.3) 0.433 Pre-emptive 1 (1.3) 7 (2.3) 0.173 Dual transplant (%) 16 (10) 28 (9.4) 0.883 Delayed graft function (%) 52 (51.2) 80 (27.1) <0.001 Discontinuation of dialysis (dy) 54 3 ± 3.1 3.3 ± 7.1 <0.002 Primary non-function (%) 8 (5) 6(2.5) 0.733 Acute rejection 16 (6.7) 25 (10.5) 0.122 Induction (thymoglobuline) 45 (28.1) 78 (23.1) 0.783 Induction (thymoglobuline) 22 (13.7) 44 (10) 0.833 Increase (w)<	Stay in the ICU	5 ± 3.4	5.1 ± 3.9	0.824
Male sex (%) 94 (88.3) 194 (65.7) 0.138 Pre-transplant panel reactive antibody (%) 24 ± 8.9 19 ± 8.5 0.774 BMI (mean, kg/m²) 27.4 26.2 0.645 Time on dialysis (mo) 61.9 ± 60 41.3 ± 41 ∞001 Hemodialysis (%) 159 (87.7) 229 (94.5) 0.885 Peritoneal dialysis (%) 0 (0) 10 (3.3) 0.433 Pre-emptive 1 (1.3) 7 (2.3) 0.173 Dual transplant (%) 16 (10) 28 (9.4) 0.883 Peritoneal dialysis (%) 8 (51.2) 80 (27.1) ∞0001 Dual transplant (%) 8 (5) (6.25) 0.733 Deal transplant (%) 8 (5) (6.25) 0.733 Acute rejection 16 (67) 25 (10.5) 0.212 Primary nor-function (%) 8 (5) (6.25) 0.733 Acute rejection 8 (5) (6.25) 0.733 Acute rejection 10 (60.7) 25 (10.5) 0.22 Induction (basilisimab) 4 (8.2) 7 (8.31)	Recipient			
Pre-transplant panel reactive antibody (%) 24 ± 8.9 19 ± 8.5 0.74 BMI (mean, kg/m²) 27.4 26.2 0.645 Time on dialysis (mo) 61.9 ± 60 41.3 ± 41 <0.001				
BMI (mean, kg/m²) 27.4 26.2 0.645 Time on dailysis (mo) 61.9 ± 60 41.3 ± 41 −0.001 Time on waiting list (mo) 20.6 ± 28 18.9 ± 25 0.502 Hemodialysis (%) 15.9 (8.7) 279 (94.5) 0.885 Pertoneal dialysis (%) 0 (0) 10 (3.3) 0.433 Pre-emptive 1 (1.3) 7 (2.3) 0.173 Dual transplant (%) 28 (51.2) 80 (27.1) −0.001 Discontinuation of dialysis (dy) 5.43 ± 3.1 3.3 ± 7.1 −0.002 Primary non-function (%) 8 (5) 6(2.5) 0.733 Acute rejection 16 (67) 25 (10.5) 0.122 Immunosuppression 16 (67) 25 (10.5) 0.122 Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 1 accrolimus 2 (16.5) 2.9 (20.7) 0.501 1 fortinus 24 (15) 48 (10.9) 0.112 2 (13.7) 44 (10) 0.883 1 fortinus 24 (15) 48 (10.9) 0.112				
Time on dialysis (mo) 61.9 ± 60 41.3 ± 41 -0.001 Time on waiting list (mo) 10.6 ± 28 18.9 ± 25 0.502 Hemodialysis (%) 15.9 (98.7) 27.9 (94.5) 0.885 Pertoneal dialysis (%) 10 (0) 10 (3.3) 0.433 Pre-emptive 1 (1.3) 7 (2.3) 0.173 Dual transplant (%) 16 (10) 28 (9.4) 0.883 Delayed graft function (%) 8.2 (51.2) 80 (27.1) -0.001 Discontinuation of dialysis (dy) 5.43 ± 3.1 3.3 ± 7.1 0.002 Primary non-function (%) 8 (5) 6(2.5) 0.733 Acute rejection 16 (6.7) 25 (10.5) 0.122 Immunosupression 8 (5) 6(2.5) 0.733 Induction (basiliximab) 45 (28.1) 78 (23.1) 0.758 Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 Tacrolimus 110 (68.5) 294 (68.9) 0.214 MMF 140 (87.5) 25 (15.6) 59 (23.1) 0.108 Everolimus <td></td> <td></td> <td></td> <td></td>				
Time on waiting list (mo) 20.6 ± 28 18.9 ± 25 0.502 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 18.9 ± 19.9 ± 18.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 18.9 ± 19.9 ± 19.9 ± 18.9 ± 19.9 ± 19.9 ± 18.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ± 19.9 ±	Time on dialysis (mo)			
Pretoneal dialysis (%) 0 (0) 10 (3.3) 0.433 Pre-emptive 1 (1.3) 7 (2.3) 0.173 Delayed graft function (%) 82 (51.2) 80 (27.1) 0.0001 Delayed graft function (%) 8.2 (51.2) 80 (27.1) 0.0001 Discontinuation of dialysis (dy) 5.43 ± 3.1 3.3 ± 7.1 0.002 Primary non-function (%) 8 (5) 6(2.5) 0.733 Acute rejection 16 (6.7) 25 (10.5) 0.122 Immunosuppression 45 (28.1) 78 (23.1) 0.753 Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 Tacrolimus 22 (13.7) 44 (10) 0.883 Tacrolimus 110 (68.5) 20 (46.9) 0.214 MMF 140 (87.5) 250 (77.7) 0.301 Sirolimus 24 (15.5) 44 (10) 0.883 Everolimus 12 (7.5) 21 (7.9) 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 21 (2.5) 11	Time on waiting list (mo)			
Pre-emptive Dual transplant (%) 16 (10) 28 (9.4) 0.883 Delayed graft function (%) 82 (51.2) 80 (27.1) <0.001				
Dula transplant (%) 16 (10) 28 (9.4) 0.883 Delayed graft function (%) \$2 (51.2) 80 (27.1) 0.001 Piscontinuation of dialysis (dy) \$4.3 ± 3.1 3.3 ± 7.1 0.002 Primary non-function (%) 8 (5) 6 (6.25) 0.733 Acute rejection 16 (6.7) 25 (10.5) 0.122 Immuosuppression Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 Tacrolimus 110 (68.5) 294 (68.9) 0.214 MMF 140 (87.5) 250 (77.7) 0.301 Sirolimus 24 (15) 48 (10.9) 0.112 Cyclosporine 25 (15.6) 59 (23.1) 0.108 Everolimus 12 (7.5) 21 (7.9) 0.32 Hostoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 52 (32.5) 195 (66.1) <0.001				
Delayed gräft function (%) 82 (51.2) 80 (27.1) <0.001 Discontinuation of dialysis dvy 5.43 ± 3.1 3.3 ± 7.1 0.002 Primary non-function (%) 8 (5) 6(2.5) 0.733 Acute rejection 16 (6.7) 25 (10.5) 0.122 Immunosuppression 18 (5) 78 (23.1) 0.753 Induction (basilisimab) 45 (28.1) 78 (23.1) 0.753 Induction (thymoglobuline) 110 (68.5) 294 (68.9) 0.214 MMF 140 (87.5) 250 (77.7) 0.301 Sirolimus 24 (15) 48 (10.9) 0.112 Cyclosporine 25 (15.6) 59 (23.1) 0.108 Everolimus 12 (7.5) 21 (7.9) 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 12 (7.5) 25 (8.4)<				
Primary non-function (%) 8 (5) 6 (2.5) 0.733 Acute rejection 16 (6.7) 25 (10.5) 0.122 Immunosuppression 8 (5) 45 (28.1) 78 (23.1) 0.753 Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 Tacrolimus 110 (68.5) 204 (68.9) 0.214 MMF 140 (87.5) 250 (77.7) 0.301 Strolimus 24 (15) 48 (10.9) 0.112 Cyclosporine 25 (15.6) 59 (23.1) 0.108 Everolimus 12 (7.5) 21 (7.9) 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 25 (32.5) 195 (66.1) <0.001 Part-time employed (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 27 (35.6) 31 (10.5) <0.001 Prestriem employed (%) 12 (7.5) 25 (8.4) 0.702 1-year serum creatinine (mg/dL) 1.66 ± 0.70	Delayed graft function (%)	82 (51.2)	80 (27.1)	< 0.001
Acute rejection 16 (6.7) 25 (10.5) 0.122 Immunosuppression Induction (basiliximab) 45 (28.1) 78 (23.1) 0.753 Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 Tacrolimus 110 (68.5) 204 (68.9) 0.214 MMF 140 (87.5) 250 (77.7) 0.301 Sirolimus 24 (15) 48 (10.9) 0.112 Cyclosporine 25 (15.6) 59 (23.1) 0.108 Everolimus 12 (7.5) 21 (7.9) 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 52 (32.5) 195 (66.1) <0.001 Part-time employed (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 24 (15) 28 (9.4) 0.080 Retired (%) 12 (7.5) 25 (8.4) 0.080 Retired (%) 12 (7.5) 25 (8.4) 0.080 Pyear serum creatinine (mg/dL) 1.46 ± 0.70 1.54 ± 0.				
Immunosuppression 45 (28.1) 78 (23.1) 0.753 Induction (basiliximab) 45 (28.1) 78 (23.1) 0.753 Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 Tacrolimus 110 (68.5) 204 (68.9) 0.214 MMF 140 (88.5) 250 (77.7) 0.301 Sirolimus 24 (15) 48 (10.9) 0.112 Cyclosporine 25 (15.6) 59 (23.1) 0.108 Everolimus 12 (7.5) 21 (7.9) 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 52 (32.5) 195 (66.1) <0.001				
Induction (basiliximab) 45 (28.1) 78 (23.1) 0.753 Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 Tacrolimus 110 (68.5) 204 (68.9) 0.214 MMR 140 (87.5) 250 (77.7) 0.301 Sirolimus 24 (15) 48 (10.9) 0.112 Cyclosporine 25 (15.6) 59 (23.1) 0.108 Everolimus 12 (7.5) 21 (7.9) 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 52 (32.5) 195 (66.1) <0.001	<u> </u>	10 (0.7)	23 (10.3)	0.122
Induction (thymoglobuline) 22 (13.7) 44 (10) 0.883 Tacrolinus 110 (88.5) 204 (88.9) 0.214 MMF 140 (87.5) 250 (77.7) 0.301 Sirolinus 24 (15) 48 (10.9) 0.112 Cyclosporine 25 (15.6) 59 (23.1) 0.108 Everolinus 12 (7.5) 21 (7.9) 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 52 (32.5) 195 (66.1) <0.001	Induction (basiliximab)	45 (28.1)	78 (23.1)	0.753
Tacrolimus MMF 110 (68.5) 204 (68.9) 0.214 MMF MMF Sirolimus Sirolimus Cyclosporine Everolimus 24 (15) 48 (10.9) 0.112 MMF MMF ME MI				
Sirolimus Cyclosporine Everolimus 24 (15) 5 (25 (156) 59 (23.1) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (7.9) (25 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12 (156) 12	Tacrolimus			
Cyclosporine Everolimus 25 (15.6) 12 (7.5) 59 (23.1) 21 (7.9) 0.108 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 52 (32.5) 195 (66.1) <0.001 Part-time employed (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 22 (1.5) 28 (9.4) 0.080 Retired (%) 57 (35.6) 31 (10.5) <0.001 Unemployed (%) 12 (7.5) 25 (8.4) 0.702 1-year serum creatinine (mg/dL) 1.41 ± 0.77 1.46 ± 0.80 0.490 5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 58 ± 12.3 59 ± 11.8 0.633 10-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 88.1% <th< td=""><td></td><td></td><td></td><td></td></th<>				
Everolimus 12 (7.5) 21 (7.9) 0.323 Hospital stay 9.8 ± 3.4 10.5 ± 5.1 0.242 Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 52 (32.5) 195 (66.1) <0.001 Part-time employed (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 24 (15) 28 (9.4) 0.080 Retired (%) 57 (35.6) 31 (10.5) <0.001 Unemployed (%) 12 (7.5) 25 (8.4) 0.702 1-year serum creatinine (mg/dL) 1.41 ± 0.77 1.46 ± 0.80 0.490 5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 85% 92.5% 0.011 10-year patient survival 85% 92.5% <th< td=""><td></td><td></td><td></td><td></td></th<>				
Postoperative death (30-day) 3 (1.8) 4 (1.3) 0.738 Employed (%) 52 (32.5) 195 (66.1) <0.001 Part-time employed (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 24 (15) 28 (9.4) 0.080 Retired (%) 57 (35.6) 31 (10.5) <0.001 Unemployed (%) 12 (7.5) 25 (8.4) 0.702 1-year serum creatinine (mg/dL) 1.41 ± 0.77 1.46 ± 0.80 0.490 5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 61 ± 11.4 63 ± 10.4 0.048 10-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8%				
Employed (%) 52 (32.5) 195 (66.1) <0.001 Part-time employed (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 24 (15) 28 (9.4) 0.080 Retired (%) 57 (35.6) 31 (10.5) <0.001	Hospital stay	9.8 ± 3.4	10.5 ± 5.1	0.242
Part-time employed (%) 2 (1.25) 11 (3.7) 0.128 Housewife (%) 24 (15) 28 (9.4) 0.080 Retired (%) 57 (35.6) 31 (10.5) <0.001 Unemployed (%) 12 (7.5) 25 (8.4) 0.702 1-year serum creatinine (mg/dL) 1.41 ± 0.77 1.46 ± 0.80 0.490 5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 61 ± 11.4 63 ± 10.4 0.048 10-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	Postoperative death (30-day)	3 (1.8)	4 (1.3)	0.738
Housewife (%) 24 (15) 28 (9.4) 0.080 Retired (%) 57 (35.6) 31 (10.5) <0.001 Unemployed (%) 12 (7.5) 25 (8.4) 0.702 1-year serum creatinine (mg/dL) 1.41 ± 0.77 1.46 ± 0.80 0.490 5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 61 ± 11.4 63 ± 10.4 0.048 10-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	Employed (%)	52 (32.5)	195 (66.1)	< 0.001
Retired (%) 57 (35.6) 31 (10.5) <0.001 Unemployed (%) 12 (7.5) 25 (8.4) 0.702 1-year serum creatinine (mg/dL) 1.41 ± 0.77 1.46 ± 0.80 0.490 5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 61 ± 11.4 63 ± 10.4 0.048 10-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	Part-time employed (%)	2 (1.25)	11 (3.7)	0.128
Unemployed (%) $12 (7.5)$ $25 (8.4)$ 0.702 1-year serum creatinine (mg/dL) 1.41 ± 0.77 1.46 ± 0.80 0.490 5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 61 ± 11.4 63 ± 10.4 0.048 10-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	Housewife (%)	24 (15)	28 (9.4)	0.080
1-year serum creatinine (mg/dL) 1.41 ± 0.77 1.46 ± 0.80 0.490 5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 61 ± 11.4 63 ± 10.4 0.048 10-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	Retired (%)	57 (35.6)	31 (10.5)	<0.001
5-year serum creatinine (mg/dL) 1.66 ± 0.70 1.54 ± 0.78 0.189 10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 61 ± 11.4 63 ± 10.4 0.048 10-year eGlomerular Filtration Rate (mL/min per 1.73 m^2) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	Unemployed (%)	12 (7.5)	25 (8.4)	0.702
10-year serum creatinine (mg/dL) 1.65 ± 0.90 1.53 ± 0.78 0.367 1-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 61 ± 11.4 63 ± 10.4 0.048 10-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year graft survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	1-year serum creatinine (mg/dL)	1.41 ± 0.77	1.46 ± 0.80	0.490
1-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 65 ± 12.4 68 ± 9.5 0.012 5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 61 ± 11.4 63 ± 10.4 0.048 10-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	5-year serum creatinine (mg/dL)	1.66 ± 0.70	1.54 ± 0.78	0.189
5-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 61 ± 11.4 63 ± 10.4 0.048 10-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	10-year serum creatinine (mg/dL)	1.65 ± 0.90	1.53 ± 0.78	0.367
10-year eGlomerular Filtration Rate (mL/min per 1.73 m²) 58 ± 12.3 59 ± 11.8 0.633 1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	1-year eGlomerular Filtration Rate (mL/min per 1.73 m²)	65 ± 12.4	68 ± 9.5	0.012
1-year patient survival 94.4% 97.6% 0.073 5-year patient survival 85% 92.5% 0.011 10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	5-year eGlomerular Filtration Rate (mL/min per 1.73 m²)	61 ± 11.4	63 ± 10.4	0.048
5-year patient survival 85% 92.5% 0.011 10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	10-year eGlomerular Filtration Rate (mL/min per 1.73 m²)	58 ± 12.3	59 ± 11.8	0.633
10-year patient survival 75.7% 83.4% 0.042 1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001	1-year patient survival	94.4%	97.6%	0.073
1-year graft survival 88.1% 96.2% 0.0008 5-year graft survival 77.6% 88.8% 0.001		85%	92.5%	0.011
5-year graft survival 77.6% 88.8% 0.001	10-year patient survival	75.7%	83.4%	0.042
· ·	1-year graft survival	88.1%	96.2%	0.0008
10-year graft survival 62.1% 75% 0.003	5-year graft survival	77.6%	88.8%	0.001
	10-year graft survival	62.1%	75%	0.003

Biomedicines **2025**, 13, 916 5 of 10

Patients with low educational status were more frequently older and male and received a kidney from donors with a longer cold ischemia time and died from cerebral hemorrhage. Moreover, patients with a low educational level had a longer time on dialysis and experienced a higher rate of delayed graft function. This would suggest that patients with a low educational level and low socio-economic status had delayed access to the health system and to the transplant waiting list, and this would have an impact on transplant outcome. As expected, patients with a low educational status were more rarely employed (66.1% vs. 32.5%, p < 0.001), with a high rate of retired patients compared to high-educational status patients (35.6% vs. 10.6%, p < 0.001). There was no significant difference in graft functionality between the two groups, as demonstrated by serum creatinine levels at 1 year (1.41 \pm 0.77 vs. 1.46 \pm 0.80 mg/dL, p = 0.440), 5 years (1.66 \pm 0.70 vs. 63 \pm 10.4 mg/dL, p = 0.189), and 10 years (1.65 \pm 0.90 vs. 1.53 \pm 0.78 mg/dL, p = 0.367).

However, the educational status had an impact on graft survival and patient survival; 1-year (88.1% vs. 96.2%, p=0.0008), 5-year (77.6% vs. 88.8%, p=0.001), and 10-year (62.1% vs. 75%, p=0.003) graft survivals were significantly lower in patients with a low educational status compared with high-educational status patients, respectively. Moreover, the Weibull model regression demonstrated that the organ failure event occurred 1.46 times faster in patients with low educational status. The low educational status had an impact also on the patient survival; 1-year (94.4% vs. 97.6%, p=0.073), 5-year (85% vs. 92.5%, p=0.011), and 10-year (75.7% vs. 83.4%, p=0.042) patient survival rates were significantly lower in patients with low educational status.

The Kaplan–Meier analysis confirmed these findings: graft survival (Figure 1) was significantly higher in patients with a high education status (p = 0.018, OR = 0.68, 95% CI = 0.497–0.935), and also patient survival was significantly better in patients with a high educational level (p = 0.041, OR = 0.68, 95% CI = 0.472–0.984).




Figure 1. Cont.

Biomedicines **2025**, 13, 916 6 of 10




Figure 1. The Kaplan–Meier analysis demonstrated worse graft (**A**) and patient (**B**) survival in patients with low educational levels compared to patients with high educational levels.

4. Discussion

Renal replacement therapy, including kidney transplantation, is a critical medical intervention for patients with ESRD, significantly impacting outcomes, costs, and quality of life improvements [6]. This study demonstrated a significant correlation between the education level of kidney transplantation recipients and post-transplant outcomes. Using a database of 456 patients, we analyzed demographic and clinical variables that could correlate with post-transplant graft and patient survival and education level. Kidney transplant recipients with a higher educational level had better survival than patients with a lower education level; the Weibull model fitting confirmed these differences, with the event of death occurring approximately 1.5 times faster in patients with a lower education level than those with a higher education level. Similar findings were found in graft survival: kidney transplant recipients with a higher education level had better graft survival compared with recipients with a low educational level. Again, the Weibull regression indicated that graft failure occurred approximately 1.46 times faster in low-education patients compared to patients with high education levels.

The educational level may influence the patients' socioeconomic status and their ability to work, thereby influencing the quality of life; however, hemodialysis patients or kidney transplant recipients experience many difficulties in maintaining employment. A recent study [27] demonstrated that employment rates in patients with ESRD are very low and decline long before initiation of dialysis or kidney transplantation. Notably, the employment rate had only a small increase after kidney transplantation. Indeed, a recent systematic review [28] demonstrated that only 26% of patients undergoing dialysis were employed and that dialysis patients with diabetes and associated co-morbidities, such as peripheral vascular disease, heart failure, and cognitive decline, had the lowest chance of being employed. Kidney transplantation could help, in principle, to remove the barrier that prevents one from working effectively; a recent study [29] demonstrated that transplanted patients had an employment rate of 56%, and this was strictly correlated with higher education level, preemptive transplantation, and receiving a living donor transplant [29,30]. This was confirmed in this study, where 66% of patients with high educational status were employed after transplantation in contrast with the 32.5% of patients with a low educational status (p < 0.001). Moreover, patients with a low educational status retired

Biomedicines **2025**, 13, 916 7 of 10

more frequently compared with those with a high educational status. However, fatigue together with memory problems, restlessness, and anxiety could constitute an obstacle to returning to work for transplant patients, even in patients with a high educational level [29]. Moreover, transplanted patients worked shorter hours and were more likely to have jobs that are mentally rather than physically demanding [29].

A higher educational level is correlated with better access to healthcare, better treatment adherence, and better post-transplant outcomes [23,24]. This could be due to several factors: patients with a higher education level may have a better understanding of the importance of adhering to the post-transplant therapeutic regimen, including taking immunosuppressive drugs regularly and attending follow-up visits; furthermore, a higher level of education may be correlated with a greater ability to navigate the healthcare system and access quality medical resources.

Although the Italian healthcare system is designed to ensure equity in access to dialysis and transplants, socioeconomic disparities continue to influence clinical outcomes and therapeutic adherence. Patients with a lower level of education are often less informed and less able to manage the complex therapeutic regimens required after transplantation, which could lead to a higher incidence of complications and reduced graft survival [18]. This was confirmed in our study: kidney transplant recipients with a low educational level had a longer time on dialysis and delayed access to the transplant health system, and these factors could negatively influence the post-transplant outcomes. Moreover, patients with a low educational status were more rarely employed, with a high rate of retired patients compared to high-educational status patients, and this could influence the perceived better quality of life associated with kidney transplantation [10,31].

Interestingly, when the socioeconomic status improves in the post-transplant period, post-transplant outcomes are positively influenced. In contrast, patients whose economic status did not improve 3 years after kidney transplantation showed a higher risk of death than those whose status improved [32].

Lower educational status has been associated with lower health literacy, which can affect a patient's ability to manage their health effectively and adhere to post-transplantation treatment protocols [20]. In contrast, higher educational status is often linked to better health outcomes due to better access to healthcare resources, increased social support, and a greater ability to comply with medical advice [21,22]. It is important to highlight some limitations of our study. The measurement of education level might be subject to misclassification bias, and the data collected might not be complete due to patients' reluctance to share certain information. Moreover, the relatively small sample size and the lack of data on some potential confounding factors might affect the generalizability of the results. Although our study showed an association between education level and post-transplant outcomes, it cannot establish a direct causal relationship. Future studies with larger samples and longitudinal study designs are needed to further explore these findings and better understand the mechanisms through which education may influence clinical outcomes. In conclusion, our study underscored the importance of considering socioeconomic factors, such as education level, in managing patients who have undergone kidney transplantation. Improving access to education and providing targeted educational support and health literacy could enhance treatment adherence and reduce disparities in transplant outcomes. Moreover, a correct and early education about kidney transplantation could help design a retraining option, resulting in the adaptation of the working conditions to the patient's needs. This approach could lead to significant improvements in the quality of life and survival of transplanted patients, contributing to a more equitable and inclusive healthcare system.

Biomedicines **2025**, 13, 916 8 of 10

Author Contributions: M.V. and F.L. provided substantial contributions to the conception or design of this study; M.M.G., G.R. (Giuseppe Roscitano), D.Z., A.M., C.D.P., M.L.P., A.D., C.C., R.G., M.S., G.R. (Giordana Riccioli) and A.G. were responsible for the acquisition, analysis, or interpretation of data for this study; M.V. and F.L. were responsible for drafting of this article; P.V. was responsible for revising this article critically for important intellectual content; M.V., F.L. and P.V. carried out the final approval of the version to be published. All authors have read and agreed to the published version of the manuscript.

Funding: This research received funding from the Department of Medical and Surgical Sciences and Advanced Technologies of the University of Catania.

Institutional Review Board Statement: This study was conducted in accordance with the principles of the 1975 Declaration of Helsinki. Data were extracted anonymously and retrospectively, and no reference to personal data of patients was retrieved. All patients gave their informed consent to use their data anonymously for research purposes. This study involved the normal practices of our institution, and for all these reasons, the Ethical Committee of the University Hospital of Catania decided to exempt this study from formal approval.

Informed Consent Statement: Informed consent was obtained from all subjects involved in this study.

Data Availability Statement: It is possible for de-identified data to be made available upon reasonable request.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- 1. Merion, R.M.; Goodrich, N.P.; Johnson, R.J.; McDonald, S.P.; Russ, G.R.; Gillespie, B.W.; Collett, D. Kidney transplant graft outcomes in 379 257 recipients on 3 continents. *Am. J. Transplant.* **2018**, *18*, 1914–1923. [CrossRef] [PubMed]
- Nielsen-Bohlman, L.; Panzer, A.M.; Kindig, D.A. Health Literacy: A Prescription to End Confusion; Committee on Health Literacy, Board on Neuroscience and Behavioral Health, National Academies Press: Washington, DC, USA, 2004.
- 3. Berkman, N.D.; Sheridan, S.L.; Donahue, K.E.; Halpern, D.J.; Crotty, K. Low health literacy and health outcomes: An updated systematic review. *Ann. Intern. Med.* **2011**, *155*, 97–107. [CrossRef]
- 4. Warsame, F.; Haugen, C.E.; Ying, H.; Garonzik-Wang, J.M.; Desai, N.M.; Hall, R.K.; Kambhampati, R.; Crews, D.C.; Purnell, T.S.; Segev, D.L.; et al. Limited health literacy and adverse outcomes among kidney transplant candidates. *Am. J. Transplant.* **2019**, *19*, 457–465. [CrossRef]
- 5. Salter, M.L.; Orandi, B.; McAdams-DeMarco, M.A.; Law, A.; Meoni, L.A.; Jaar, B.G.; Sozio, S.M.; Kao, W.H.; Parekh, R.S.; Segev, D.L. Patient- and provider-reported information about transplantation and subsequent waitlisting. *J. Am. Soc. Nephrol.* **2014**, 25, 2871–2877. [CrossRef]
- 6. Salter, M.L.; Gupta, N.; King, E.; Bandeen-Roche, K.; Law, A.H.; McAdams-DeMarco, M.A.; Meoni, L.A.; Jaar, B.G.; Sozio, S.M.; Kao, W.H.; et al. Health-related and psychosocial concerns about transplantation among patients initiating dialysis. *Clin. J. Am. Soc. Nephrol.* **2014**, *9*, 1940–1948. [CrossRef] [PubMed]
- 7. Dageforde, L.A.; Box, A.; Feurer, I.D.; Cavanaugh, K.L. Understanding Patient Barriers to Kidney Transplant Evaluation. *Transplantation* **2015**, 99, 1463–1469. [CrossRef]
- 8. Basu, M.; Petgrave-Nelson, L.; Smith, K.D.; Perryman, J.P.; Clark, K.; Pastan, S.O.; Pearson, T.C.; Larsen, C.P.; Paul, S.; Patzer, R.E. Transplant Center Patient Navigator and Access to Transplantation among High-Risk Population: A Randomized, Controlled Trial. Clin. J. Am. Soc. Nephrol. 2018, 13, 620–627. [CrossRef] [PubMed]
- 9. Gillespie, A.; Hammer, H.; Lee, J.; Nnewihe, C.; Gordon, J.; Silva, P. Lack of listing status awareness: Results of a single-center survey of hemodialysis patients. *Am. J. Transplant.* **2011**, *11*, 1522–1526. [CrossRef]
- De Pasquale, C.; Pistorio, M.L.; Corona, D.; Mistretta, A.; Zerbo, D.; Sinagra, N.; Giaquinta, A.; Tallarita, T.; Esker, B.; Mociskyte, D.; et al. Correlational study between psychic symptoms and quality of life among hemodialysis patients older than 55 years of age. *Transplant. Proc.* 2012, 44, 1876–1878. [CrossRef]
- 11. Green, J.A.; Mor, M.K.; Shields, A.M.; Sevick, M.A.; Palevsky, P.M.; Fine, M.J.; Arnold, R.M.; Weisbord, S.D. Prevalence and demographic and clinical associations of health literacy in patients on maintenance hemodialysis. *Clin. J. Am. Soc. Nephrol.* **2011**, *6*, 1354–1360. [CrossRef]

Biomedicines **2025**, 13, 916 9 of 10

12. Taylor, D.M.; Bradley, J.A.; Bradley, C.; Draper, H.; Dudley, C.; Fogarty, D.; Fraser, S.; Johnson, R.; Leydon, G.M.; Metcalfe, W.; et al. ATTOM investigators. Limited health literacy is associated with reduced access to kidney transplantation. *Kidney Int.* **2019**, 95, 1244–1252. [CrossRef] [PubMed]

- 13. Kaboré, R.; Couchoud, C.; Macher, M.A.; Salomon, R.; Ranchin, B.; Lahoche, A.; Roussey-Kesler, G.; Garaix, F.; Decramer, S.; Pietrement, C.; et al. Age-Dependent Risk of Graft Failure in Young Kidney Transplant Recipients. *Transplantation* **2017**, 101, 1327–1335. [CrossRef]
- 14. Lepeytre, F.; Dahhou, M.; Zhang, X.; Boucquemont, J.; Sapir-Pichhadze, R.; Cardinal, H.; Foster, B.J. Association of Sex with Risk of Kidney Graft Failure Differs by Age. *J. Am. Soc. Nephrol.* **2017**, *28*, 3014–3023. [CrossRef] [PubMed]
- 15. Boucquemont, J.; Pai, A.L.H.; Dharnidharka, V.R.; Hebert, D.; Furth, S.L.; Foster, B.J. Gender Differences in Medication Adherence Among Adolescent and Young Adult Kidney Transplant Recipients. *Transplantation* **2019**, 103, 798–806. [CrossRef]
- 16. Lennerling, A.; Petersson, I.; Andersson, U.M.; Forsberg, A. Health Literacy among patients with end-stage kidney disease and kidney transplant recipients. *Scand. J. Caring Sci.* **2021**, 35, 485–491. [CrossRef] [PubMed]
- 17. Taylor, D.M.; Fraser, S.; Dudley, C.; Oniscu, G.C.; Tomson, C.; Ravanan, R.; Roderick, P.; ATTOM investigators. Health literacy and patient outcomes in chronic kidney disease: A systematic review. *Nephrol. Dial. Transplant.* **2018**, *33*, 1545–1558. [CrossRef]
- Naylor, K.L.; Knoll, G.A.; Shariff, S.Z.; McArthur, E.; Garg, A.X.; Van Walraven, C.; Austin, P.C.; McCallum, M.K.; Quinn, R.R.;
 Tan, V.S.; et al. Socioeconomic Status and Kidney Transplant Outcomes in a Universal Healthcare System: A Population-based Cohort Study. *Transplantation* 2019, 103, 1024–1035. [CrossRef]
- 19. Mistretta, A.; Veroux, M.; Grosso, G.; Contarino, F.; Biondi, M.; Giuffrida, G.; Gagliano, M.; Giaquinta, A.; Zerbo, D.; Tallarita, T.; et al. Role of socioeconomic conditions on outcome in kidney transplant recipients. *Transplant. Proc.* **2009**, *41*, 1162–1167. [CrossRef]
- 20. Huang, S.; Xia, X.; Lai, W.; Hao, X.; Wu, Y.; Lv, K.; Luo, Z.; Romão, E.A.; Ciancio, G.; Lv, C.; et al. Effects of recipient education disparity on living donor kidney transplant outcomes across different ethnic groups: A retrospective study in the United States. *Trans. Androl. Urol.* 2023, 12, 1137–1154. [CrossRef]
- 21. Ghods, A.J.; Nasrollahzadeh, D. Noncompliance with immunnosuppressive medications after renal transplantation. *Exp. Clin. Transplant.* **2003**, *1*, 39–47.
- 22. Goldfarb-Rumyantzev, A.S.; Sandhu, G.S.; Barenbaum, A.; Baird, B.C.; Patibandla, B.K.; Narra, A.; Koford, J.K.; Barenbaum, L. Education is associated with reduction in racial disparities in kidney transplant outcome. *Clin. Transplant.* **2012**, *26*, 891–899. [CrossRef] [PubMed]
- 23. Hod, T.; Goldfarb-Rumyantzev, A.S. The role of disparities and socioeconomic factors in access to kidney transplantation and its outcome. *Ren. Fail.* **2014**, *36*, 1193–1199. [CrossRef]
- 24. Schold, J.D.; Buccini, L.D.; Kattan, M.W.; Goldfarb, D.A.; Flechner, S.M.; Srinivas, T.R.; Poggio, E.D.; Fatica, R.; Kayler, L.K.; Sehgal, A.R. The association of community health indicators with outcomes for kidney transplant recipients in the United States. *Arch. Surg.* 2012, 147, 520–526. [CrossRef]
- 25. Veroux, M.; Zerbo, D.; Basile, G.; Gozzo, C.; Sinagra, N.; Giaquinta, A.; Sanfiorenzo, A.; Veroux, P. Simultaneous Native Nephrectomy and Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease. *PLoS ONE* **2016**, *11*, e0155481. [CrossRef]
- 26. Veroux, M.; Sanfilippo, F.; Roscitano, G.; Giambra, M.; Giaquinta, A.; Riccioli, G.; Zerbo, D.; Corona, D.; Sorbello, M.; Veroux, P. Prevention of Delayed Graft Function in Kidney Transplant Recipients through a Continuous Infusion of the Prostaglandin Analogue Iloprost: A Single-Center Prospective Study. Biomedicines 2024, 12, 290. [CrossRef]
- 27. Carlsen, R.K.; Kirkeskov, L.; Riis, M.S.; Jacobsen, R.K.; Gronemann, F.H.; Osler, M.; Petersen, J.; Buus, N.H. Employment before and after initiation of dialysis or kidney transplantation- a Danish nationwide registry-based cohort study. *BMC Nephrol.* **2025**, 26, 48. [CrossRef] [PubMed]
- 28. Kirkeskov, L.; Carlsen, R.K.; Lund, T.; Buus, N.H. Employment of patients with kidney failure treated with dialysis or kidney transplantation: A systematic review and meta-analysis. *BMC Nephrol.* **2024**, 22, 2021. [CrossRef] [PubMed]
- 29. Knobbe, T.J.; Kremer, D.; Abma, F.I.; Annema, C.; Berger, S.P.; Navis, G.J.; van der Mei, S.F.; Bültmann, U.; Visser, A.; Bakker, S.J.L.; et al. Employment Status and Work Functioning among Kidney Transplant Recipients. *Clin. J. Am. Soc. Nephrol.* **2021**, 17, 1506–1514. [CrossRef]
- 30. Visser, A.; Alma, M.A.; Bakker, S.J.L.; Bemelman, F.J.; Berger, S.P.; van der Boog, P.J.M.; Brouwer, S.; Hilbrands, L.B.; Standaar, D.S.M.; Stewart, R.E.; et al. Employment and ability to work after kidney transplantation in the Netherlands: The impact of preemptive versus non-preemptive kidney transplantation. *Clin. Transplant.* 2022, 36, e14757. [CrossRef]

Biomedicines **2025**, 13, 916

31. Grubman-Nowak, M.; Dębska-Ślizień, A.; Renke, M. Employment after renal transplantation vs. the health locus of control and the quality of life. *Int. J. Occup. Med. Environ. Health* **2022**, *35*, 53–62. [CrossRef]

32. Park, S.; Park, J.; Jeong, J.; Jang, Y.; Kim, Y.C.; Kim, D.K.; Oh, K.H.; Joo, K.W.; Kim, Y.S.; Lee, H. Changes in socioeconomic status and patient outcomes in kidney transplantation recipients in South Korea. *Korean J. Transplant.* 2023, 37, 29–40. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.